BioCentury | Jul 20, 2017
Product R&D

Inducing competition for MSCs

...a variety of sources. Mesoblast Ltd. (ASX:MSB; NASDAQ:MESO) acquired Temcell HS remestemcel-L (then Prochymal) from Osiris Therapeutics Inc....
BioCentury | Jun 30, 2017
Company News

Management tracks

...will assume Couturier's responsibilities. Bristol-Myers Squibb Co. (NYSE:BMY) acquired Cardioxyl in 2015. Regenerative medicines company Osiris Therapeutics Inc....
BioCentury | Oct 11, 2016
Company News

Management tracks

...CEO Stephen Aselage will lead R&D while the company recruits a replacement. Regenerative medicine company Osiris Therapeutics Inc....
BioCentury | Feb 9, 2016
Company News

Management tracks

...company Osiris Therapeutics Inc. (NASDAQ:OSIR) said CEO Lode Debrabandere resigned. CBO Dwayne Montgomery will be interim CEO. Osiris...
BioCentury | Nov 9, 2015
Clinical News

CHAM: Phase III started

...The trial includes an open-label extension. SOC includes debridement, a non-adherent dressing and standardized off-loading. Osiris Therapeutics Inc....
BioCentury | Sep 18, 2015
Company News

Management tracks

...Dubow was VP of medical affairs at Cynapsus Therapeutics Inc. (Toronto, Ontario). Regenerative medicine company Osiris Therapeutics Inc....
...and Dwayne Montgomery to CBO. Law was VP of finance and principal accounting officer at Osiris...
BioCentury | Apr 10, 2015
Company News

Management tracks

...of R&D. Spetzler succeeds Joachim Schorr, who left the post last fall. Regenerative medicine company Osiris Therapeutics Inc....
BioCentury | Dec 15, 2014
Company News

Osiris management update

Osiris Therapeutics Inc. (NASDAQ:OSIR), Columbia, Md. Business: Cancer, Cardiovascular, Musculoskeletal Hired: Jon Hopper as CMO, formerly VP and global medical director at Stryker Corp. WIR Staff cancer Cardiovascular Musculoskeletal...
BioCentury | Nov 3, 2014
Company News

Osiris, Arthrex deal

...Osiris granted Arthrex exclusive development and commercialization rights to Cartiform . Osiris will be responsible for...
...restore cartilage repair. Osiris declined to provide additional details, and Arthrex could not be reached. Osiris Therapeutics Inc....
BioCentury | May 5, 2014
Company News

California Institute for Regenerative Medicine management update

...as president and CEO, effective "in the next few weeks," formerly president and CEO of Osiris Therapeutics Inc....
Items per page:
1 - 10 of 255
BioCentury | Jul 20, 2017
Product R&D

Inducing competition for MSCs

...a variety of sources. Mesoblast Ltd. (ASX:MSB; NASDAQ:MESO) acquired Temcell HS remestemcel-L (then Prochymal) from Osiris Therapeutics Inc....
BioCentury | Jun 30, 2017
Company News

Management tracks

...will assume Couturier's responsibilities. Bristol-Myers Squibb Co. (NYSE:BMY) acquired Cardioxyl in 2015. Regenerative medicines company Osiris Therapeutics Inc....
BioCentury | Oct 11, 2016
Company News

Management tracks

...CEO Stephen Aselage will lead R&D while the company recruits a replacement. Regenerative medicine company Osiris Therapeutics Inc....
BioCentury | Feb 9, 2016
Company News

Management tracks

...company Osiris Therapeutics Inc. (NASDAQ:OSIR) said CEO Lode Debrabandere resigned. CBO Dwayne Montgomery will be interim CEO. Osiris...
BioCentury | Nov 9, 2015
Clinical News

CHAM: Phase III started

...The trial includes an open-label extension. SOC includes debridement, a non-adherent dressing and standardized off-loading. Osiris Therapeutics Inc....
BioCentury | Sep 18, 2015
Company News

Management tracks

...Dubow was VP of medical affairs at Cynapsus Therapeutics Inc. (Toronto, Ontario). Regenerative medicine company Osiris Therapeutics Inc....
...and Dwayne Montgomery to CBO. Law was VP of finance and principal accounting officer at Osiris...
BioCentury | Apr 10, 2015
Company News

Management tracks

...of R&D. Spetzler succeeds Joachim Schorr, who left the post last fall. Regenerative medicine company Osiris Therapeutics Inc....
BioCentury | Dec 15, 2014
Company News

Osiris management update

Osiris Therapeutics Inc. (NASDAQ:OSIR), Columbia, Md. Business: Cancer, Cardiovascular, Musculoskeletal Hired: Jon Hopper as CMO, formerly VP and global medical director at Stryker Corp. WIR Staff cancer Cardiovascular Musculoskeletal...
BioCentury | Nov 3, 2014
Company News

Osiris, Arthrex deal

...Osiris granted Arthrex exclusive development and commercialization rights to Cartiform . Osiris will be responsible for...
...restore cartilage repair. Osiris declined to provide additional details, and Arthrex could not be reached. Osiris Therapeutics Inc....
BioCentury | May 5, 2014
Company News

California Institute for Regenerative Medicine management update

...as president and CEO, effective "in the next few weeks," formerly president and CEO of Osiris Therapeutics Inc....
Items per page:
1 - 10 of 255